Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from InnoCan Pharma ( (TSE:INNO) ) is now available.
Innocan Pharma has secured its first patent in India for its Liposomal CBD Injection platform, marking a significant milestone in its efforts to advance non-opioid treatments for chronic pain management. This patent strengthens Innocan’s proprietary value in the $55 billion Indian pharmaceutical market, as it continues to collaborate with global experts to maximize the therapeutic effects of cannabinoids through innovative drug delivery systems.
More about InnoCan Pharma
Innocan Pharma is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan has developed a CBD-loaded liposome drug delivery platform for precise dosing and prolonged release of synthetic CBD, aimed at non-opioid pain management. In the wellness sector, the company develops and markets a wide range of self-care and beauty products focused on promoting healthier lifestyles through targeted online sales.
YTD Price Performance: -8.09%
Average Trading Volume: 14,000
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $38.39M
For detailed information about INNO stock, go to TipRanks’ Stock Analysis page.
